Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
InDex Pharmaceuticals are present at UEGW 2022, informing about our novel drug candidate cobitolimod and the ongoing phase III study CONCLUDE in moderate to severe left-sided ulcerative colitis.
InDex Pharmaceuticals is developing cobitolimod for the treatment of moderate to severe ulcerative colitis
Capital Markets Day 2022
-
InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod
January 27, 2023 Regulatory
-
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2022
November 23, 2022 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q3 for January-September 2022 on November 23 2022 at 08:00 a.m. CET.
-
Year-end Report 2022
-
Annual Report 2022
-
Interim Report Q1 2023
Our phase III study CONCLUDE
Have a look at InDex’s corporate presentation
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
